Michael Koteles
Endocrinology, Diabetes & Metabolism · Travis Afb, CANPI 1093799959
Payments from drug & device makers
Across 512 payments — averaging $20.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Lilly USA, LLC$1K
- Abbott$887
- AstraZeneca$812
- Novo Nordisk$777
- Boehringer Ingelheim$757
- plus $5K from 35 others
What the payments were for
- Consulting fees$2352%
- Food & beverage$9,85996%
- Education$140%
- Gifts$1091%
- Other$400%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 52 | $1,182 |
| Lilly USA, LLC | 64 | $1,028 |
| Abbott | 37 | $887 |
| AstraZeneca(2 entities) | 40 | $812 |
| Novo Nordisk | 47 | $777 |
| Boehringer Ingelheim | 36 | $757 |
| Mannkind Corporation | 25 | $493 |
| Sanofi-aventis U.S. LLC | 28 | $450 |
| Radius Health, Inc. | 16 | $347 |
| Merck | 18 | $347 |
| Medtronic(2 entities) | 11 | $293 |
| Corcept Therapeutics | 15 | $275 |
| Xeris Pharmaceuticals, Inc. | 12 | $261 |
| Amarin Pharma, Inc. | 13 | $213 |
| AbbVie | 6 | $211 |
| Johnson & Johnson | 13 | $200 |
| Insulet Corporation | 12 | $195 |
| Regeneron Healthcare Solutions, Inc. | 7 | $171 |
| Dexcom, Inc. | 8 | $161 |
| Bayer | 8 | $153 |
| BD | 7 | $132 |
| IBSA Pharma Inc. | 6 | $104 |
| Esperion Therapeutics, Inc. | 4 | $88 |
| Tandem Diabetes Care, Inc. | 4 | $88 |
| Novartis | 3 | $75 |
| Shire North American Group Inc | 3 | $68 |
| BETA Bionics, Inc. | 2 | $62 |
| GSK | 1 | $60 |
| Zealand Pharma US, Inc. | 2 | $56 |
| Sekisui Diagnostics LLC | 1 | $50 |
| Antares Pharma, Inc. | 1 | $47 |
| Cequr Corporation | 1 | $35 |
| Senseonics, Incorporated | 1 | $32 |
| Pfizer | 1 | $23 |
| Gilead | 1 | $21 |
| Exact Sciences | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Smith+Nephew | 1 | $18 |
| Lifescan, Inc. | 1 | $14 |
| Bigfoot Biomedical Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolia$175
- FREESTYLE LIBRE 3$140
- FreeStyle Libre 2$134
- JARDIANCE$125
- EEA$116
How this compares
$10,257 in reported general payments places this provider in the 75th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 174 | $216,370 |
| TrulicityDulaglutide | 98 | $115,825 |
| MounjaroTirzepatide | 109 | $110,831 |
| JardianceEmpagliflozin | 90 | $100,111 |
| TymlosAbaloparatide | 25 | $64,255 |
| FarxigaDapagliflozin Propanediol | 50 | $53,609 |
| KerendiaFinerenone | 37 | $40,676 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 29 | $34,983 |
| ProliaDenosumab | 13 | $20,947 |
| JanuviaSitagliptin Phosphate | 12 | $16,685 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $16,061 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 15 | $15,022 |
| VascepaIcosapent Ethyl | 16 | $13,534 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $9,886 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 27 | $8,344 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $1,028 | $229,989234 claims |
| Novo NordiskOzempic | $777 | $216,370174 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $757 | $141,823130 claims |
| Radius Health, Inc.Tymlos | $347 | $64,25525 claims |
| AstraZenecaFarxiga | $812 | $53,60950 claims |
| BayerKerendia | $153 | $40,67637 claims |
| AmgenProlia | $1,182 | $20,94713 claims |
| MerckJanuvia | $347 | $16,68512 claims |
| AbbVieSynthroid | $211 | $1,20021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Travis Afb
- Jerrold OlefskySan Diego$26.5M
- Mark ChristiansenWalnut Creek$22.9M
- Timothy BaileyEscondido$22.3M
- Stanley HsiaLos Angeles$19.8M
- Juan FriasSan Diego$14.1M
- Paul NorwoodFresno$6.2M
- Athena Philis-Tsimikasla Jolla$6M
- David AhnNewport Beach$5.8M
- Shlomo MelmedLos Angeles$3.3M
- Leila ChaychiSan Carlos$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.